Pipeline › ecnoglutide
ecnoglutide
Not FDA-approved, and in phase 3 development, not authorised in the European Union. 4 active trials, the next due to complete 2027-12-16.
GLP-1 agonist, SC, from Sciwind Biosciences. Every figure below is taken directly from ClinicalTrials.gov, Drugs@FDA, the FDA Drug Shortage Database, the EMA register or Europe PMC, and re-checked every four hours.
- Status
- phase3
- Target
- GLP-1
- Route
- SC
- Sponsor
- Sciwind Biosciences
- First FDA approval
- Not approved
- EU authorisation
- Not authorised
- Active trials
- 4 (4 in phase 3)
- Participants enrolled
- 832
- Trials with a reporting date
- 4
- Approved FDA submissions
- 0
Recent changes
When these trials report
Next 4 of 4 active trials by estimated primary completion.
| Est. completion | Trial | Sponsor | Phase | Participants |
|---|---|---|---|---|
| 2027-12-16 | A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy NCT07387094 · Change from baseline in Apnea-Hypopnea Index (AHI) | Hangzhou Sciwind Biosciences Co., Ltd. | P3 | 140 |
| 2028-05-31 | A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA) NCT07734311 · Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score | Hangzhou Sciwind Biosciences Co., Ltd. | P3 | 360 |
| 2028-06-08 | A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents NCT07836270 · Percent change in Body Mass Index (BMI) | Hangzhou Sciwind Biosciences Co., Ltd. | P3 | 192 |
| 2028-06-19 | A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy NCT07434050 · Change from baseline in Apnea-Hypopnea Index (AHI) | Hangzhou Sciwind Biosciences Co., Ltd. | P3 | 140 |
Indications under study
Adolescents With Obesity; Adolescents With Overweight & Weight-related Comorbidities; Knee Osteoarthritis; OSA - Obstructive Sleep Apnea; Obesity.
Recent papers
| Published | Title | Journal |
|---|---|---|
| 2026-09-11 | Dose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy Feng Y, Sun C, Li X, Hu L, Zhou K, Li L, Yuan Y, Yu L, Wu M, Liu L. | Front Endocrinol (Lausanne) |
| 2026-07-07 | Ecnoglutide: First Approvals Shirley M. | Drugs |
| 2026-06-17 | Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants Li F, Du C, Yu Q, Feng S, Cai L, Chen Z, Zou Q, Guo W, Du D, Hu F, Liu X, Huang Y, Shi S, Shi W, Guan L, Yang L, Zheng Q, Li Y, Liu R, Yang M. | Diabetes Obes Metab |
| 2026-05-01 | Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis Kumar M, Kumar S, Ali SME, Qazi H, Janjua AA, Ahmed H, Babar R, Sheikh RI, Kumar L, Ali SM, Hanif F, Gul K, Ali AS, Bukhari SUR, Raja A, Chaulagain A. | Endocrinol Diabetes Metab |
| 2026-04-29 | No dose adjustment required for warfarin or metformin when coadministered with the novel GLP-1 receptor agonist ecnoglutide: an open-label, fixed-sequence, crossover study Chen Z, Du C, Cai L, Feng S, Zou Q, Guo W, Li F, Du D, Hu F, Liu X, Huang Y, Shi S, Shi W, Yu Q, Zhang L, Guan L, Yang L, Li Y, Liu R, Ning J, Yang M, Zheng Q. | Front Pharmacol |
| 2026-01-07 | Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial Zhu D, Wang W, Tong G, Ma J, Wen B, Zheng X, Shi B, Pang S, Wang K, Shi X, Zhang X, Fu L, Liu Y, Lu Y, Huang D, Jiang C, Pan T, Xue H, Han J, Ding H, Bing S, Jiang F, Zheng Q, Yang M, Guan L, Liu X, Ning J, Bu Y, Guo M, Yang L, Guo W, Li Y, Xu S, Pan H. | Nat Commun |
| 2025-08-22 | Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial He Y, Mi N, Cheng Z, Xue H, Han J, Wang H, Wang H, Wu J, Shi X, Zhao S, Duan B, Zhu Y, Zhou Y, Li F, Wang X, Ling H, Wang S, Li Q, Jiang F, Yang M, Bing S, Zheng Q, Ning J, Guo M, Bu Y, Guan L, Li Y, Yang L, Guo W, Pan H, Li X. | Lancet Diabetes Endocrinol |
| 2025-08-22 | Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management? Scheen AJ. | Lancet Diabetes Endocrinol |
| 2025-06-21 | Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Ji L, Gao L, Xue H, Tian J, Wang K, Jiang H, Huang C, Lian Q, Yuan M, Gao G, Lu Y, Han J, Fu W, Wang H, Zhang Y, Shi X, Wen B, Shi B, Hu W, Guo T, Xing Y, Li Y, Li Q, Zheng Q, Yang M, Ning J, Guo M, Li Y, Pan H. | Lancet Diabetes Endocrinol |
| 2025-05-22 | Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a randomised, double-blind, placebo-controlled, phase 3 trial Bing s, Zhu D, Wang W, Tong G, Ma J, Wen B, Zheng X, Shi B, Pang S, Wang K, Shi X, Zhang X, Fu L, Liu Y, lu Y, Huang D, Jiang C, Pan T, Xue H, Han J, Ding H, Jiang F, Zheng Q, Yang M, Guan L, Liu X, Ning J, Bu Y, Guo M, Yang L, Guo W, Li Y, Xu S, Pan H. | Research Square preprint |
| 2024-09-27 | Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial Zhu D, Wang W, Tong G, Ma G, Ma J, Han J, Zhang X, Liu Y, Gan S, Qin H, Zheng Q, Ning J, Zhu Z, Guo M, Bu Y, Li Y, Jones CL, Fenaux M, Junaidi MK, Xu S, Pan H. | Nat Commun |
| 2023-06-24 | Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog Guo W, Xu Z, Zou H, Li F, Li Y, Feng J, Zhu Z, Zheng Q, Zhu R, Wang B, Li Y, Hao S, Qin H, Jones CL, Adegbite E, Telusca L, Fenaux M, Zhong W, Junaidi MK, Xu S, Pan H. | Mol Metab |
Every ecnoglutide trial on file
All 8 registered trials of ecnoglutide, largest first. Each links to its own page and to the registry record.